Tirzepatide cuts diabetes risk by 90% in obese patients, study shows
Tirzepatide, a new injectable weight-loss drug with the trade name Zepbound, reduced the risk of diabetes in patients with obesity and prediabetes by more than
Tirzepatide, a new injectable weight-loss drug with the trade name Zepbound, reduced the risk of diabetes in patients with obesity and prediabetes by more than
The City University of New York (CUNY) Institute for Implementation Science in Population Health (ISPH) and the CUNY Graduate School of Public Health and Health
Welcome to Endpoints News’ manufacturing news briefs, where we bring you essential news on new builds, collaborations, recalls and more. This week we look into